FGFR tyrosine kinase inhibitors for the treatment of urothelial cell carcinoma

摘要

Described herein are methods of treating urothelial cell carcinoma using an approved pharmaceutical product containing a fibroblast growth factor receptor (FGFR) inhibitor. Also described herein are methods of marketing or making available for sale an approved pharmaceutical product containing a fibroblast growth factor receptor (FGFR) inhibitor.